If technology allowed humanity to live forever in the future, would you take the ticket? We asked our readers recently and were surprised to see the balance tilt towards “No” (60% of respondents). One answer was hidden in a comment from one of our readers – they would want to live forever, yet only if they stayed young. Among others, living long worries people as it is associated with getting old and suffering from various diseases.Yet if technology allows us to extend our life spans it will also likely improve our health spans. According to demographers, children today have a better chance of living up to 100 years old than ever before. But their lives won’t be just longer, they will also benefit from day-to-day technological advances aimed at improving their well-being, preventing diseases, and keeping their minds and bodies in shape.Slowing aging presents an economic opportunity, too. In the US, an estimate shows that just one to two years increase in life expectancy are worth between $7 trillion and $38 trillion

Hans Bishop and Steve Harr know a few things about biotech. The pair once worked together at Seattle flagship cell therapy company Juno Therapeutics, where Bishop was CEO and Harr was COO and CFO.

After a bustling, record-setting 2020 for private biotechs raising cash, the bar heading into 2021 was exceptionally high. Turns out, private investors elected to just take the bar and do pull-ups, breaking 2020’s record by a whopping 26%.  | 2021 marked the second consecutive year of record-breaking private financing for biotechs, with more than $28 billion raised. The total haul is a 26% increase from 2020, and the stunning dollar amounts came even as the public market depreciated throughout the year. Here's our look at the 10 biotechs that raked in the largest VC investments.